A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

NCT02811679 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Study closed early due to slow accrual

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: Blinatumomab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]